Ultimovacs has announced topline data from the phase II NIPU trial assessing the universal cancer vaccine UV1 in mesothelioma. An independent review of the results has concluded that the primary endpoint, progression-free survival, has not been reached. Meanwhile a local assessment has found a statistically significant improvement in PFS for patients receiving UV1 treatment. BioStock spoke with Jens Bjørheim, CMO at Ultimovacs, to get a full overview of the results.
Watch the interview with Ultimovacs‘ CMO Jens Bjørheim below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.